Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 13/2022

25-07-2022 | Lung Cancer | Original Article

Presence of non-Newtonian fluid in invasive pulmonary mucinous adenocarcinomas impacts fluorescence during intraoperative molecular imaging of lung cancer

Authors: Feredun Azari, Gregory Kennedy, Ashley Chang, Bilal Nadeem, Neil Sullivan, Isvita Marfatia, Azra Din, Charuhas Desphande, John Kucharczuk, Edward J. Delikatny, Sunil Singhal

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 13/2022

Login to get access

Abstract

Background

Intraoperative molecular imaging (IMI) with folate-targeted NIR tracers has been shown to improve lesion localization in more than 80% of lung adenocarcinomas. However, mucinous adenocarcinomas (MAs) and invasive mucinous adenocarcinomas (IMAs) of the lung, which are variants of adenocarcinoma, appear to have decreased fluorescence despite appropriate folate receptor expression on the tumor surface. We hypothesized that the etiology may be related to light excitation and emission through non-Newtonian fluid (mucin) produced by goblet and columnar cancer cells.

Methods

Intraoperative data for 311 subjects were retrospectively reviewed from a prospectively collected 6-year database. For standardization, all patients underwent infusion of the same targeted molecular optical contrast agent (pafolacianine, folate receptor-targeted NIR fluorochrome) for lung cancer resections. Then, the ratio of the mean fluorescence intensity of the tumors and background tissues (TBR) was calculated. Tumors were examined for mucin, FRa, FRb, and immunofluorescent tracer uptake by a board-certified pathologist. The optical properties of mucin analyzed by imaging software were used to create in vitro gel models to explore the effects on NIR tracer fluorescence intensity.

Results

A large proportion (192, 62%) of the patients were female, with an average of 62.8 years and a 34-year mean pack smoking history. There were no severe (Clavien–Dindo > III) complications related to pafolacianine infusion. A total of 195 lesions in the study were adenocarcinomas, of which 19 (6.1%) were of the mucinous subtype. A total of 14/19 of the patients had a smoking history, and more than 74% of the IMA lesions were in the lower lobes. IMA lesions had a lower in situ TBR than nonmucinous adenocarcinomas (2.64 SD 0.23) vs (3.45 SD 0.11), respectively (p < 0.05). Only 9/19 (47%) were localized in situ. Tumor bisection and removal of mucin from IMAs significantly increased pafolacianine fluorescence, with resultant TBR not being significantly different from the control group (4.67 vs 4.89) (p = 0.19). Of the 16 lesions that underwent FR expression analysis, 15/16 had FR presence on cancer cells or tumor-associated macrophages in the tumor microenvironment. There was no statistically significant difference in fluorescence intensity during immunofluorescence analysis (4.99 vs 5.08) (p = 0.16). Physical removal of mucin from IMAs improved the TBR from 3.11 to 4.67 (p < 0.05). In vitro analysis of the impact of synthetic non-Newtonian fluid (agarose 0.5%) on NIR tracer fluorescence showed a decrease in MFI by a factor of 0.25 regardless of the concentration for each 5 mm thickness of mucin.

Conclusion

The mucinous subtype of lung adenocarcinomas presents a unique challenge in pafolacianine-targeted IMI-guided resections. The presence of non-Newtonian fluids presents a physical barrier that dampens the excitation of the tracer and fluorescence emission detected by the camera. Knowledge of this phenomenon can allow the surgeon to critically analyze lesion fluorescence parameters during IMI-guided lung cancer resections.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wood R, Taylor-Stokes G. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage. BMC Cancer. 2019;19:214.CrossRef Wood R, Taylor-Stokes G. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage. BMC Cancer. 2019;19:214.CrossRef
2.
go back to reference Xia W, et al. Improvement of survival for non-small cell lung cancer over time. Onco Targets Ther. 2017;10:4295–303.CrossRef Xia W, et al. Improvement of survival for non-small cell lung cancer over time. Onco Targets Ther. 2017;10:4295–303.CrossRef
3.
go back to reference Heuvers ME, Hegmans JP, Stricker BH, Aerts JG. Improving lung cancer survival; time to move on. BMC Pulm Med. 2012;12:77.CrossRef Heuvers ME, Hegmans JP, Stricker BH, Aerts JG. Improving lung cancer survival; time to move on. BMC Pulm Med. 2012;12:77.CrossRef
5.
go back to reference Azari F, Kennedy G, Singhal S. Intraoperative detection and assessment of lung nodules. Surg Oncol Clin. 2020;29:525–41.CrossRef Azari F, Kennedy G, Singhal S. Intraoperative detection and assessment of lung nodules. Surg Oncol Clin. 2020;29:525–41.CrossRef
6.
go back to reference Azari F, et al. Intraoperative molecular imaging clinical trials: a review of 2020 conference proceedings. JBO. 2021;26:050901.PubMedCentral Azari F, et al. Intraoperative molecular imaging clinical trials: a review of 2020 conference proceedings. JBO. 2021;26:050901.PubMedCentral
7.
go back to reference Chi C, et al. Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology. Theranostics. 2014;4:1072–84.CrossRef Chi C, et al. Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology. Theranostics. 2014;4:1072–84.CrossRef
9.
go back to reference O’Shannessy DJ, et al. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget. 2012;3:414–25.CrossRef O’Shannessy DJ, et al. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget. 2012;3:414–25.CrossRef
10.
11.
go back to reference Predina JD, et al. Identification of a folate receptor-targeted near-infrared molecular contrast agent to localize pulmonary adenocarcinomas. Mol Ther. 2018;26:390–403.CrossRef Predina JD, et al. Identification of a folate receptor-targeted near-infrared molecular contrast agent to localize pulmonary adenocarcinomas. Mol Ther. 2018;26:390–403.CrossRef
12.
go back to reference Newton AD, Predina JD, Nie S, Low PS, Singhal S. Intraoperative fluorescence imaging in thoracic surgery. J Surg Oncol. 2018;118:344–55.CrossRef Newton AD, Predina JD, Nie S, Low PS, Singhal S. Intraoperative fluorescence imaging in thoracic surgery. J Surg Oncol. 2018;118:344–55.CrossRef
14.
go back to reference Travis WD, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–60.CrossRef Travis WD, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–60.CrossRef
15.
go back to reference Goldstein NS, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol. 2001;116:319–25.CrossRef Goldstein NS, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol. 2001;116:319–25.CrossRef
16.
go back to reference Shim HS, et al. Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. J Thorac Oncol. 2015;10:1156–62.CrossRef Shim HS, et al. Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. J Thorac Oncol. 2015;10:1156–62.CrossRef
17.
go back to reference Yoshizawa A, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24:653–64.CrossRef Yoshizawa A, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24:653–64.CrossRef
18.
go back to reference Lai SK, Wang Y-Y, Wirtz D, Hanes J. Micro- and macrorheology of mucus. Adv Drug Deliv Rev. 2009;61:86–100.CrossRef Lai SK, Wang Y-Y, Wirtz D, Hanes J. Micro- and macrorheology of mucus. Adv Drug Deliv Rev. 2009;61:86–100.CrossRef
19.
go back to reference Chen S, et al. Understanding optical reflectance contrast for real-time characterization of epithelial precursor lesions. Bioeng Transl Med. 2019;4:e10137.CrossRef Chen S, et al. Understanding optical reflectance contrast for real-time characterization of epithelial precursor lesions. Bioeng Transl Med. 2019;4:e10137.CrossRef
21.
23.
go back to reference Shi J, Li D, Liang D, He Y. Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China. Sci Rep. 2021;11:6817.CrossRef Shi J, Li D, Liang D, He Y. Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China. Sci Rep. 2021;11:6817.CrossRef
24.
go back to reference Thomas A, Chen Y, Yu T, Jakopovic M, Giaccone G. Trends and characteristics of young non-small cell lung cancer patients in the United States. Front Oncol. 2015;5:113.CrossRef Thomas A, Chen Y, Yu T, Jakopovic M, Giaccone G. Trends and characteristics of young non-small cell lung cancer patients in the United States. Front Oncol. 2015;5:113.CrossRef
25.
go back to reference Sagerup CMT, Småstuen M, Johannesen TB, Helland Å, Brustugun OT. Sex-specific trends in lung cancer incidence and survival: a population study of 40 118 cases. Thorax. 2011;66:301–7.CrossRef Sagerup CMT, Småstuen M, Johannesen TB, Helland Å, Brustugun OT. Sex-specific trends in lung cancer incidence and survival: a population study of 40 118 cases. Thorax. 2011;66:301–7.CrossRef
26.
go back to reference Kennedy GT, et al. The optical biopsy: a novel technique for rapid intraoperative diagnosis of primary pulmonary adenocarcinomas. Ann Surg. 2015;262:602–9.CrossRef Kennedy GT, et al. The optical biopsy: a novel technique for rapid intraoperative diagnosis of primary pulmonary adenocarcinomas. Ann Surg. 2015;262:602–9.CrossRef
27.
go back to reference Zargham M, Moradi A-R, Najafi A. Experimental investigation of surface tension in Newtonian and non-Newtonian fluids with optical diffractometry. In Martins Costa MFPC, editors. Proc. SPIE 8785, 8th Iberoamerican Optics Meeting and 11th Latin American Meeting on Optics, Lasers, and Applications, 8785DN (2013). https://doi.org/10.1117/12.2026373. Zargham M, Moradi A-R, Najafi A. Experimental investigation of surface tension in Newtonian and non-Newtonian fluids with optical diffractometry. In Martins Costa MFPC, editors. Proc. SPIE 8785, 8th Iberoamerican Optics Meeting and 11th Latin American Meeting on Optics, Lasers, and Applications, 8785DN (2013). https://​doi.​org/​10.​1117/​12.​2026373.
28.
go back to reference Eberhard U, et al. Mapping the local viscosity of non-Newtonian fluids flowing through disordered porous structures. Sci Rep. 2020;10:11733.CrossRef Eberhard U, et al. Mapping the local viscosity of non-Newtonian fluids flowing through disordered porous structures. Sci Rep. 2020;10:11733.CrossRef
29.
go back to reference Cao, J. et al. Recent progress in NIR-II contrast agent for biological imaging. Frontiers in Bioengineering and Biotechnology 7, (2020) Cao, J. et al. Recent progress in NIR-II contrast agent for biological imaging. Frontiers in Bioengineering and Biotechnology 7, (2020)
Metadata
Title
Presence of non-Newtonian fluid in invasive pulmonary mucinous adenocarcinomas impacts fluorescence during intraoperative molecular imaging of lung cancer
Authors
Feredun Azari
Gregory Kennedy
Ashley Chang
Bilal Nadeem
Neil Sullivan
Isvita Marfatia
Azra Din
Charuhas Desphande
John Kucharczuk
Edward J. Delikatny
Sunil Singhal
Publication date
25-07-2022
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 13/2022
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-022-05912-8

Other articles of this Issue 13/2022

European Journal of Nuclear Medicine and Molecular Imaging 13/2022 Go to the issue